SCHEMBL3535539

SCHEMBL3535539

CC(C)OC(=O)N1CCCC(=O)c2ccccc21

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 3/20 0.48
MAPT P10636 2/20 0.47
HTT P42858 3/20 0.44
LMNA P02545 2/20 0.44
RAB9A P51151 1/20 0.44
P2RX4 Q99571 1/20 0.43
BCHE P06276 1/20 0.43
ALDH1A1 P00352 6/20 0.43
HPGD P15428 3/20 0.43
TSHR P16473 1/20 0.43
AGTR1 P30556 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
SCN9A Q15858 1/20 0.40
SCN10A Q9Y5Y9 1/20 0.40
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5669846 0.83 NOTUM (0.63) NOTUMMAPTHTTLMNAALDH1A1
SCHEMBL3530779 0.82 ABHD6 (0.44) MAPTLMNARAB9AALDH1A1HPGD
SCHEMBL3532281 0.82 SLC6A15 (0.41) NOTUMALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL2475561 0.82 ABHD6 (0.46) MAPTLMNARAB9AALDH1A1HPGD
SCHEMBL3537930 0.81 MEN1 (0.42) NOTUMMAPTLMNAP2RX4BCHE
SCHEMBL29960283 0.81 KDM1A (0.48) NOTUMMAPTHTTLMNARAB9A
SCHEMBL14380662 0.81 KDM1A (0.48) NOTUMMAPTHTTLMNARAB9A
SCHEMBL3528833 0.80 SCN9A (0.47) NOTUMMAPTLMNAP2RX4BCHE
SCHEMBL11888090 0.80 KDM4E (0.39) MAPTLMNARAB9AALDH1A1HPGD
SCHEMBL4774750 0.80 KDM4E (0.34) NOTUMMAPTLMNARAB9AP2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7749992-B2 Compounds and methods for treating dislipidemia ELI LILLY AND COMPANY (US) 2010-07-06 US disclosed
EP-2098512-A1 Compounds and methods for treating dyslipidemia Eli Lilly & Company (US) 2009-09-09 EP disclosed
EP-1670768-B1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA LILLY CO ELI (US) 2009-09-09 EP disclosed
US-20070254869-A1 Compounds And Methods For Treating Dislipidemia ELI LILLY AND COMPANY (US) 2007-11-01 US disclosed
EP-1670768-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2006-06-21 EP disclosed
WO-2005037796-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254869-A1 Compounds And Methods For Treating Dislipidemia APOB, CETP, PCSK9 NOTUM 303/4885MAPT 4605/4885HTT 1252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.